Federal Report Urgs States to Plan Now for Psychedelics FDA Approval

Federal Working Group Flags Two-Year Window

The report identifies a narrow implementation window between FDA approval and state readiness, urging immediate action on licensing, prescriber training, and insurance coverage rules. FDA approval of MDMA-assisted therapy for PTSD is expected by mid-2027. Psilocybin for treatment-resistant depression will likely follow by early 2028. The working group—convened by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Centers for Medicare & Medicaid Services (CMS), and the Office of National Drug Control Policy (ONDCP)—analyzed state preparedness across 23 regulatory domains.

Only six states have begun drafting psychedelic-specific medical frameworks, the analysis found, despite the fact that FDA approval will immediately reclassify these substances under the Controlled Substances Act. States without advance preparation risk a regulatory vacuum in which federally approved medicines remain inaccessible due to state-level barriers, the report warns.

The working group reviewed Oregon's Measure 109 psilocybin program and Colorado's Natural Medicine Health Act as early models, but noted that neither framework is designed for FDA-approved prescription medicines. Oregon's system prohibits take-home doses and requires all sessions to occur in licensed service centers. Those requirements conflict with the MAPS MDMA protocol, which includes at-home integration periods.

Medicaid Coverage and Reimbursement Gaps

The report identifies Medicaid reimbursement as the single largest barrier to equitable access, with most states lacking coverage pathways for multi-hour assisted-therapy sessions. CMS analysis cited in the document shows that typical psychedelic-assisted therapy sessions last 6-8 hours, far exceeding the billing structures used for conventional outpatient psychiatry. Without advance state planning, Medicaid programs may default to denying coverage or reimbursing at rates that make treatment economically unviable for providers.

States should begin modeling reimbursement frameworks now, using the MAPS Phase 3 trial protocols as cost benchmarks, the working group recommends. MDMA-assisted therapy for PTSD requires three 8-hour sessions plus 12 preparatory and integration visits, with estimated total costs between $12,000 and $15,000 per patient. Psilocybin protocols are similar in structure and cost.

States are urged to establish coverage parity rules that prevent insurers from imposing stricter prior-authorization or step-therapy requirements on psychedelic medicines than on conventional psychiatric drugs. Oregon's psilocybin program, which is entirely out-of-pocket, has served fewer than 800 patients in its first two years. That's a utilization rate the working group describes as "far below public-health need."

Licensing, Training, and Enforcement Coordination

The report calls for immediate development of facilitator licensing standards, prescriber training requirements, and cross-agency enforcement protocols to avoid the fragmentation that plagued early cannabis legalization. The working group reviewed lessons from medical cannabis rollouts in 38 states and identified three recurring failures: unclear scope-of-practice rules for non-physician facilitators, inconsistent training standards across state lines, and poor coordination between health departments, medical boards, and controlled-substance agencies.

For psychedelic medicines, the working group recommends that states adopt a tiered licensing model distinguishing between prescribers (physicians, nurse practitioners, and physician assistants with specialized training) and facilitators (licensed therapists or trained non-clinicians who provide session support but don't prescribe). The report suggests a minimum 40-hour training requirement for facilitators, modeled on Oregon's 160-hour curriculum but streamlined for integration into existing mental-health licensing pathways.

States are also urged to clarify enforcement authority before FDA approval. Without advance coordination, state medical boards may lack jurisdiction over non-physician facilitators, while behavioral-health agencies may lack authority over controlled substances. That creates gaps in oversight. Governors should designate a lead agency now and convene cross-departmental task forces to draft unified rules, the working group recommends.

The report doesn't provide a formal implementation timeline, but the working group's recommendations are structured around a 24-month planning horizon. For comprehensive background on the FDA approval pathway and state-level dynamics, see the CannIntel topic hub on psychedelics FDA approval.

The next major federal signal will be the FDA's advisory committee review of Lykos Therapeutics' MDMA new drug application, currently scheduled for Q2 2027. State regulators watching that calendar have less than a year to draft frameworks before the approval decision arrives.